"Etanercept" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant version of soluble human TNF receptor that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.
| Descriptor ID |
D000068800
|
| MeSH Number(s) |
D12.776.124.486.485.114.619.393.261 D12.776.124.790.651.114.619.393.261 D12.776.377.715.548.114.619.393.261 D12.776.543.750.705.852.760.232
|
| Concept/Terms |
TNFR-Fc Fusion Protein- TNFR-Fc Fusion Protein
- Fusion Protein, TNFR-Fc
- Protein, TNFR-Fc Fusion
- TNFR Fc Fusion Protein
- TNR-001
- TNR001
- TNR 001
- 001, TNR
- TNT Receptor Fusion Protein
- TNTR-Fc
|
Below are MeSH descriptors whose meaning is more general than "Etanercept".
Below are MeSH descriptors whose meaning is more specific than "Etanercept".
This graph shows the total number of publications written about "Etanercept" by people in this website by year, and whether "Etanercept" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Etanercept" by people in Profiles.
-
Melanoma risk during immunomodulating treatment. Melanoma Res. 2022 12 01; 32(6):411-418.
-
Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti-Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti-Tumor Necrosis Factor on B Cells. Arthritis Rheumatol. 2022 02; 74(2):200-211.
-
Tumor necrosis factor inhibition attenuates white matter gliosis after systemic inflammation in preterm fetal sheep. J Neuroinflammation. 2020 Mar 23; 17(1):92.
-
Sustained response to rituximab in a TNFi-induced ANCA-vasculitis developed in a patient with rheumatoid arthritis. Semin Arthritis Rheum. 2018 02; 47(4):e15-e16.
-
Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatr Rheumatol Online J. 2017 Jun 13; 15(1):50.
-
End-stage renal disease in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2017 02; 46(4):418-422.
-
Total pancreatectomy with islet autotransplantation: summary of a National Institute of Diabetes and Digestive and Kidney diseases workshop. Pancreas. 2014 Nov; 43(8):1163-71.
-
Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas. 2013 Jul; 42(5):813-8.
-
Ankylosing spondylitis in a patient referred to physical therapy with low back pain. Physiother Theory Pract. 2012 Jan; 28(1):63-70.
-
Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol. 2006 Apr 20; 24(12):1852-9.